🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Sabra Health Care REIT director Catherine Cusack buys $101k in stock

Published 24/05/2024, 00:04
© Reuters.
SBRA
-

In a recent move, Catherine Cusack, a director at Sabra Health Care REIT (NYSE:WELL), Inc. (NASDAQ:SBRA), acquired shares of the company's stock valued at approximately $101,010. The purchase, which took place on May 22, 2024, involved 7,000 shares at a price of $14.43 each. Following the transaction, Cusack's holdings in the company increased to a total of 46,385 shares.

This purchase demonstrates a vote of confidence from a key member of Sabra Health Care REIT's board in the company's future prospects. Investors often keep a close eye on insider transactions as they can provide insights into the executive's view of the company's valuation and potential.

It's worth noting that the total shares now owned by Cusack include 1,014 unvested stock units and 33,371 stock units that have vested but have not yet been paid out. These stock units are effectively a right to receive shares of the company's common stock in the future.

As with all insider transactions, this recent purchase was publicly disclosed in compliance with SEC regulations, providing transparency for investors and the market. The details of the transaction, including the number of shares acquired and the price paid per share, offer a glimpse into the director's investment moves and can be an indicator for investors when considering their own positions in Sabra Health Care REIT, Inc.

InvestingPro Insights

In light of the recent insider purchase by director Catherine Cusack, Sabra Health Care REIT, Inc. (NASDAQ:SBRA) demonstrates several financial metrics that could be of interest to investors. According to InvestingPro data, Sabra Health Care REIT has a market capitalization of $3.28 billion and is trading at a Price/Earnings (P/E) ratio of 66.4, which adjusts to 32.24 when looking at the last twelve months as of Q1 2024. This suggests a valuation that may be more attractive when considering near-term earnings growth.

The company's revenue growth was 21.68% over the last twelve months as of Q1 2024, indicating a healthy expansion in its operations. Additionally, the dividend yield as of the latest data point stands at 8.48%, which is significant and reflects the company's commitment to returning value to shareholders, having maintained dividend payments for 14 consecutive years.

InvestingPro Tips for Sabra Health Care REIT highlight that the company is expected to be profitable this year, with net income anticipated to grow. Moreover, the company is trading at a high earnings multiple, which might be justified by its revenue growth and consistent dividend payments. For investors seeking more in-depth analysis, there are additional tips available on InvestingPro, which can be accessed at https://www.investing.com/pro/SBRA. Using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a total of 9 InvestingPro Tips that can further inform investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.